Table I.
Patient characteristics.
| Characteristics | No. of patients (n=31) | % |
|---|---|---|
| Age, years | ||
| Median (range) | 58.5 (37–83) | |
| Gender | ||
| Male | 16 | 51.6 |
| Female | 15 | 48.4 |
| Histotype | ||
| Adenocarcinoma | 30 | 96.8 |
| Undifferentiated | 1 | 3.2 |
| ECOG performance status | ||
| 0 | 0 | 0.0 |
| 1 | 30 | 96.8 |
| 2 | 1 | 3.2 |
| Response to initial PBC | ||
| PR | 19 | 61.3 |
| SD | 12 | 38.7 |
| Response to PBC rechallenge | ||
| PR | 5 | 16.1 |
| SD | 17 | 54.8 |
| PD | 9 | 29.1 |
| PFS after initial PBC, months | ||
| <10 | 14 | 45.2 |
| ≥10 | 17 | 54.8 |
| TFS after initial PBC, months | ||
| <3 | 8 | 25.8 |
| ≥3 | 23 | 74.2 |
| Line of therapy with rechallenge | ||
| 2nd | 11 | 35.5 |
| 3rd | 7 | 22.6 |
| ≥4th | 13 | 41.9 |
ECOG, Eastern Cooperative Oncology Group; PBC, pemetrexed-based chemotherapy; PFS, progression-free survival; PR, partial response; SD, stable disease; PD, progressive disease; TFS, treatment-free survival.